home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  June 19, 2018
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[1] [3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 556 active entries

Vybion, Inc.

33 Thornwood Dr.
Ithaca, NY 14850
United States of America, New York

Phone: 607-266-0860
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.

Description:

Vybion uses proprietary technologies to validate drug targets and develop therapeutic drugs for unmet needs.  INT41, an Intrabody disease modifying drug delivered as a Gene Therapy for the treatment of Huntington's disease (HD) a lethal neurodegenerative disease.   INT41 prevents oligomer and aggregate formation of mutant Huntingtin protein and gene dysregulation. Both cell-based and animal models have demonstrated efficacy and mechanism of action.  Other Intrabody programs are directed at precise targeting of protein-protein interactions coupled with gene expression profiling to identify and validate drug targets for subsequent small molecule discovery. 

Selected Categories:

Product Company   Service Company
Biopharma
- General

Last update of this entry: March 10, 2015

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.